• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Sweden·Healthcare·EPIS-B.ST
Share

Episurf Medical AB Stocks

SEK 0.06Last Updated 23.10.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

SEK 4.69M

SEK 0.06
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in Germany, Sweden, rest of Europe, the United States, and internationally. It provides Episealer Knee for repairing focal cartilage and bone defects to reduce pain and increase mobility in the patient’s knee joint; Episealer implant, which is designed to fit anatomy and size of the lesion; Episealer toolkit; and Episealer Patellofemoral System, a system to treat osteoarthritis limited to the patellofemoral part of the knee joint. The company also offers Epioscopy to identify and visualize femoral knee joint cartilage and bone lesions, and tibia, as well as defects on the cruciate ligaments and menisci; Epiguide, a surgical drill guide; and µiFidelity, a web platform for order management, communication, personalized design, and surgical pre-planning. In addition, it is developing Episealer MTP implant, an implant for the MTP joint of the big toe in the foot. Further, the company offers Talus Osteotomy Guide (TOG) that is designed to fit on the patient’s distal tibia using CT and MRI images; MRI protocol to ensure correct damage assessment, 3D visualization, and device design; and Damage Marking Report (DMR) that enables 3D visualization of damage in the joint surface and underlaying bone defects, as well as other findings relevant when selecting the right treatment for the patient. The company was formerly known as Diamorph Medtech AB and changed its name to Episurf Medical AB (publ) in 2010. Episurf Medical AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA, underp

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of EPIS-B.ST is 0.10 and suggests 64.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

26.10.2026 23:40

Buyers of the foldable iPhone have complained about screen damage. How does this affect the stock price?

26.10.2026 23:02

One of Wall Street's leading optimists has withdrawn his "bullish" recommendation on the stock

26.10.2026 22:15

Revolut has begun offering consumer loans in the U.K. What does this mean for the company?

26.10.2026 21:31

Tesla shares surged: Barclays advised buying them ahead of the merger with SpaceX

26.10.2026 21:09

"We Decided Not to Delay": What Analysts Are Saying About Anthropic's IPO Prospectus

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026